

References

I-203

1. McCullough R. Elimination of unplanned treatment breaks and dose reductions caused by mucositis: Positive implications for survival outcomes and cost reductions using high potency polymerized cross-linked sucralfate in 55 patients undergoing radiation for head and neck cancer with and without chemotherapy. *Korean J Clin Oncol*. 2017;13(1):10-24.
2. McCullough R. Outsized Treatment Effects of High Potency Polymerized Cross-Linked Sucralfate (ProThelial) for Oral and Gastrointestinal Chemoradiation Mucositis – The Level of Evidence and Implication for National Cancer Center Network Category 2A Recommendations. *J Clin Oncol Res*. 2018;1(1):1-16.
3. Lalla R, Bowen J, Barasch A, et al. MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy. *Cancer*. 2014:1453-1461.